期刊文献+

异噻唑(啉)酮取代的间苯二甲酸衍生物的设计、合成及其抑制β-分泌酶活性 被引量:1

Design,synthesis and inhibitory activity against β-secretase of isothiazolone(isothiazolidine) substituted isophthalic acid derivatives
原文传递
导出
摘要 目的发现新结构的β-分泌酶抑制剂。方法基于β-分泌酶抑制剂的构效关系,设计合成了含羟乙胺结构片段的间位1,1-二氧代-2,3-(2H)-异噻唑酮和1,1-二氧代-异噻唑啉酮取代的间苯二甲酸衍生物;利用时间分辨荧光法(TRF)和中国仓鼠卵巢细胞(CHO,APP/BACE1基因)模型分别评价这些化合物体外抑制β-分泌酶和Aβ40的活性。结果合成了16个新目标化合物,利用MS和1H-NMR对化合物的结构进行了确证,利用HPLC对化合物的纯度进行了测定,利用旋光仪测定了化合物的比旋光度。活性数据显示,化合物2d、2e、2f、2g、2h和3d、3h抑制β-分泌酶活性的IC50值在10 nmol.L-1以下,化合物2c和3c、3g抑制β-分泌酶活性的IC50值在25 nmol.L-1以下;化合物2c、2d和2h在浓度为0.01μmol.L-1时,对双转APP/BACE1基因CHO细胞Aβ40产生的抑制率分别为58.3%、43.7%和42.1%。结论发现了新的β-分泌酶抑制剂,分析了其初步的构效关系,为进一步的结构优化以及发现活性更好的化合物提供了指导。 Alzheimer's disease(AD),the neurodegenerative disorder,is the most common form of dementia and no disease modification therapy is currently available.It is characterized pathologically by the presence of intracellular neurofibrillary tangles(NFTs)and extracellular amyloid plaques.According to the amyloid cascade hypothesis,accumulation of amyloid peptides(Aβ) in the brain is the main component of senile plaques results in neuronal toxicity and cell death.That is considered to play a central role in the patho-logy and subsequent cognitive decline of AD.Aβ is produced from amyloid precursor protein(APP) by the sequential cleavage of the β-and γ-secretase.Because the initial proteolytic cleavage of APP by β-secretase(also known as BACE1,memapsin-2 or Asp-2) is considered to be the rate-limiting step in the processing of APP to Aβ,BACE1 has being considered to be an attractive therapeutic target to slow or halt the progression of AD.Based on the structural feature of active site of β-secretase binding to the typical inhibitors and the structure of β-secretase inhibitors discovered in our laboratory,new P2 isothiazolone(isothiazolidine) substituted isophthalic acids combining HEA isosteres as BACE1 inhibitors were designed and synthesized in this paper.Sixteen target compounds were synthesized and their structures were confirmed by 1H-NMR and MS.The purity of these compounds was determined by HPLC.The time-resolved fluorescence technique was used to evaluate inhibitory activity of these compounds against BACE-1.For the potent inhibitors the BACE1 cellular activities were determined measuring production of secreted soluble Aβ40 in cultured HuAPPswe/HuBACE1 double transfection Chinese hamster ovary(CHO) cells.The results showed that the IC50 value of compound 2d,2e,2f,2g,2h,3d and 3h against β-secretase was low than 10 nmol·L-1 and 2c,3c and 3g was low than 25 nmol·L-1.The inhibitory rate of compounds 2c,2d and 2h against Aβ40 production was 58.3%,43.7% and 42.1% at 0.01 μmol·L-1 respectively.
出处 《中国药物化学杂志》 CAS CSCD 2012年第4期257-267,共11页 Chinese Journal of Medicinal Chemistry
基金 国家自然科学基金项目(81172924) 北京市自然科学基金项目(7112106)
关键词 Β-分泌酶 抑制剂 设计 合成 构效关系 β-secretase inhibitor design synthesis structure-activity relationship
  • 相关文献

参考文献8

  • 1HARDY J A, HIGGINS G A. Alzheimer's disease: the amyloid cascade hypothesis[J]. Science, 1992, 256 (5054) : 184 - 185.
  • 2SHANTA B, YONA L, MICHAEL R S. Inhibiting β- secretase activity in Alzheimer's disease cell models with single chain antibodies specifically targeting APP [J]. J Mol Biol,2011,405(2) :436 -447.
  • 3COLE S L, VASSAR R. BACE1 structure and function in health and Alzheimer' s disease[J]. Curr Alzheimer Res ,2008,5 ( 2 ) : 100 - 120.
  • 4GHOSH A K, BRINDISI M, TANG J. Developing β- secretase inhibitors for treatment of Alzheimer's disease [J]. J Neurochem, 2012, 120 ( Suppl. 1 ) : 71 - 83.
  • 5高善云,顾为,程军平,程肖蕊,周文霞,聂爱华.异噻唑酮取代的间苯二甲酸衍生物的设计、合成及其抑制β-分泌酶活性[J].中国药物化学杂志,2010,20(6):467-475. 被引量:2
  • 6吴杰,顾为,程肖蕊,周禹,林汉森,周文霞,聂爱华.N-甲基异噻唑酮取代的间苯二甲酸衍生物的设计、合成及其抑制β-分泌酶活性[J].中国药物化学杂志,2011,21(6):415-422. 被引量:2
  • 7HUSSAIN I, HAWKINS J, HARRISON D, et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases t-cleavage of amyloid precursor protein and amyloid-β production in vivo [J]. J Neurochem,2007,100( 3 ) :802 - 809.
  • 8HAMADA Y, KISO Y. Recent progress in the drug discovery of non-peptidic BACE1 inhibitors [ J ]. Expert Opin Drug Discov,2009,4(4) :391 -416.

二级参考文献27

  • 1HARDY J,HIGGINS G A. Alzheimer's diseases:the amyloid cascade hypothesis [ J]. Science, 1992,256 (5054) : 184 - 185.
  • 2SELKOE D J. Translating cell biology into therapeu- tic advances in Alzheimer' s diseases [ J ]. Nature, 1999,399(6738 Suppl) :A23 - A3t.
  • 3GHOSH A K,KUMARAGURUBARAN N, HONG L,et al. Design, synthesis, and X-ray structure of po- tent memapsin 2(β-secretase) inhibitors with isoph- thalamide derivatives as the P2-P3-ligands[ J]. J Med Chem,2007,50 (10) : 2399 - 2407.
  • 4YOSHIO H,YOSHIAKI K. Recent progress in the drug discovery of non-pepfidic BACE1 inhibitors[ J]. Expert Opin Drug Discov,2009,4(4) :391 -416.
  • 5GHOSH A K,SHIN D,DOWNS D,et al. Design of potent inhibitors for human brain memapsin 2 (beta- secretase) [ J ]. J Am Chem Soc, 2000, 122 ( 14 ) : 3522 - 3523.
  • 6HONG L,TURNER R T,KOELSCH G,et al. Crys- tal structure of memapsin 2(β-secretase) in complex with an inhibitor OM00-3 [ J ]. Biochemistry, 2002, 41 (36) : 10963 - 10967.
  • 7SHAWN J S, CRAIG A C, THOMAS G S, et al. Structure-based design of potent and selective cell- permeable inhibitors of human β-secretase( BACE-1 ) [J]. J Med them,2004,47(26) :6447 -6450.
  • 8CRAIG A C, SHAWN J S, KRISTEN G J, et al. BACE-1 inhibition by a series of ψ[CH2NH] re- duced amide isosteres [ J]. Bioorg Med Chem Lett, 2006,16(14) :3635 - 3638.
  • 9CHARRIER N, CLARKE B,CUTLER L,et al. Se- cond generation of hydroxyethylamine BACE-1 inhi- bitors: optimizing potency and oral bioavailability [ J]. J Med Chem ,2008 ,51 ( 11 ) :3313 -3317.
  • 10KORTUM S W,BENSON T E,BIENKOWSKI M J, et al. Potent and selective isophthalamide S2 hydroxy- ethylamine inhibitors of BACE1 [ J ]. Bioorg Med Chem Lett,2007,17 (12) :3378 - 3383.

共引文献2

同被引文献75

  • 1Hardy JA, Higgins GA. Alzheimer′s disease: the amyloid cascade hypothesis [J].Science, 1992, 256(5054): 184-185.
  • 2Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease [J].J Clin Invest, 2012, 122(4): 1377- 1392.
  • 3Vassar R, Kandalepas PC. The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer′s disease [J].Alzheimers Res Ther, 2011, 3(3): 1-6.
  • 4Yuan J, Venkatraman S, Zheng Y, et al. Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of alzheimer′s disease [J].J Med Chem, 2013, 56(11): 4156-4180.
  • 5Ghosh AK, Osswald HL. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer′s disease [J].Chem Soc Rev, 2014, 43(19): 6765-6813.
  • 6Oehlrich D, Prokopcova H, Gijsen HJM. The evolution of amidine-based brain penetrant BACE1 inhibitors [J].Bioorg Med Chem Lett, 2014, 24 (9): 2033-2045.
  • 7Hong L, Koelsch G, Lin X, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor [J].Science, 2000, 290(5489): 150-153.
  • 8Stachel SJ, Coburn CA, Steele TG, et al. Conformationally biased P3 amide replacements of β-secretase inhibitors [J].Bioorg Med Chem Lett, 2006, 16(3): 641- 644.
  • 9Stauffer SR, Stanton MG, Gregro AR, et al. Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind beta-secretase in a N-terminal 10s-loop down conformation [J].Bioorg Med Chem Lett, 2007, 17(6): 1788-1792.
  • 10Coburn CA, Stachel SJ, Jones KG, et al. BACE-1 inhibition by a series of ψ[CH2NH] reduced amide isosteres [J].Bioorg Med Chem Lett, 2006, 16(14): 3635-3638.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部